ReP USP - Resultado da busca

Artigo de periodico
METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours (2022)
Glasberg, Joao; Talans, Aley; Giollo, Thomas Rivelli; Recchimuzzi, Debora Zachello; Bezerra Neto, Joao Evangelista; Lopez, Rossana Veronica Mendonza; Hoff, Paulo Marcelo Gehm ; Riechelmann, Rachel P
Source: Ecancermedicalscience. Unidade: FM
Subjects: NEUROENDOCRINOLOGIA, CARCINOMA NEUROENDÓCRINO, NEOPLASIAS, METFORMINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GLASBERG, Joao et al. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedicalscience, v. 16, 2022Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2022.1369. Acesso em: 06 nov. 2024.
APA
Glasberg, J., Talans, A., Giollo, T. R., Recchimuzzi, D. Z., Bezerra Neto, J. E., Lopez, R. V. M., et al. (2022). METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedicalscience, 16. doi:10.3332/ecancer.2022.1369
NLM
Glasberg J, Talans A, Giollo TR, Recchimuzzi DZ, Bezerra Neto JE, Lopez RVM, Hoff PMG, Riechelmann RP. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours [Internet]. Ecancermedicalscience. 2022 ; 16[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2022.1369
Vancouver
Glasberg J, Talans A, Giollo TR, Recchimuzzi DZ, Bezerra Neto JE, Lopez RVM, Hoff PMG, Riechelmann RP. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours [Internet]. Ecancermedicalscience. 2022 ; 16[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2022.1369
Artigo de periodico
Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group (2020)
Riechelmann, Rachel; Peixoto, Renata D'Alpino; Fernandes, Gustavo Dos Santos; Weschenfelder, Rui F; Prolla, Gabriel; Rocha Filho, Duilio; Andrade, Aline Chaves; Crosara, Marcela; Rego, Juliana Florinda M; Hoff, Paulo Marcelo Gehm
Source: Ecancermedicalscience. Unidade: FM
Subjects: COVID-19, NEOPLASIAS, SISTEMA DE SAÚDE, RADIOTERAPIA, PÂNCREAS, ESÔFAGO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIECHELMANN, Rachel et al. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience, v. 14, 2020Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2020.1048. Acesso em: 06 nov. 2024.
APA
Riechelmann, R., Peixoto, R. D. 'A., Fernandes, G. D. S., Weschenfelder, R. F., Prolla, G., Rocha Filho, D., et al. (2020). Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience, 14. doi:10.3332/ecancer.2020.1048
NLM
Riechelmann R, Peixoto RD'A, Fernandes GDS, Weschenfelder RF, Prolla G, Rocha Filho D, Andrade AC, Crosara M, Rego JFM, Hoff PMG. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group [Internet]. Ecancermedicalscience. 2020 ; 14[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2020.1048
Vancouver
Riechelmann R, Peixoto RD'A, Fernandes GDS, Weschenfelder RF, Prolla G, Rocha Filho D, Andrade AC, Crosara M, Rego JFM, Hoff PMG. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group [Internet]. Ecancermedicalscience. 2020 ; 14[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2020.1048
Artigo de periodico
Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1 (2018)
Caires-lima, Rafael; Hoff, Paulo M
Source: Ecancermedicalscience. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, CUIDADOS PALIATIVOS, PROGNÓSTICO, SOBREVIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAIRES-LIMA, Rafael e HOFF, Paulo M. Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. Ecancermedicalscience, v. 12, 2018Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2018.831. Acesso em: 06 nov. 2024.
APA
Caires-lima, R., & Hoff, P. M. (2018). Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. Ecancermedicalscience, 12. doi:10.3332/ecancer.2018.831
NLM
Caires-lima R, Hoff PM. Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1 [Internet]. Ecancermedicalscience. 2018 ; 12[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2018.831
Vancouver
Caires-lima R, Hoff PM. Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1 [Internet]. Ecancermedicalscience. 2018 ; 12[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2018.831

USP Schools

ReP

Filtros

Authors

Subjects